Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Pollock

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Kidney & Blood Pressure Research|May 23, 2015
Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?Albina Nowak, Ferruh Artunc, Andreas L Serra, et al.
The Journal of Infection|October 17, 2012
Needles and the damage done: reasons for admission and financial costs associated with injecting drug use in a Central London Teaching HospitalMichael Marks, Emily Pollock, Margaret Armstrong, et al.
Nature Immunology|October 7, 2021
The legacy of maternal SARS-CoV-2 infection on the immunology of the neonateSarah Gee, Manju Chandiramani, Jeffrey Seow, et al.
Frontiers in Immunology|July 15, 2021
Mapping T Cell Responses to Native and Neo-Islet Antigen Epitopes in at Risk and Type 1 Diabetes SubjectsSefina Arif, Irma Pujol-Autonell, Yogesh Kamra, et al.
BMC Health Services Research|May 12, 2026
Harmonising research data to support mental health services decision making and care planning: development of a data harmonisation platform in regional AustraliaAgatha Conrad, Jamin Day, Ross Tynan, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapyJames McAuliffe, Hok Fung Chan, Laurine Noblecourt, et al.
Journal of Medical Virology|July 21, 2022
Concordance of B- and T-cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19Marc F Österdahl, Eleni Christakou, Deborah Hart, et al.
Cancer Research Communications|February 24, 2023
Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with CancerDuncan R McKenzie, Rosalind Graham, Thomas Lechmere, et al.
Journal for Immunotherapy of Cancer|June 28, 2020
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trialFederica Cappuccini, Richard Bryant, Emily Pollock, et al.
The Lancet. Rheumatology|November 15, 2021
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort studySatveer K Mahil, Katie Bechman, Antony Raharja, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Kidney & Blood Pressure Research|May 23, 2015
Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?Albina Nowak, Ferruh Artunc, Andreas L Serra, et al.
The Journal of Infection|October 17, 2012
Needles and the damage done: reasons for admission and financial costs associated with injecting drug use in a Central London Teaching HospitalMichael Marks, Emily Pollock, Margaret Armstrong, et al.
Nature Immunology|October 7, 2021
The legacy of maternal SARS-CoV-2 infection on the immunology of the neonateSarah Gee, Manju Chandiramani, Jeffrey Seow, et al.
Frontiers in Immunology|July 15, 2021
Mapping T Cell Responses to Native and Neo-Islet Antigen Epitopes in at Risk and Type 1 Diabetes SubjectsSefina Arif, Irma Pujol-Autonell, Yogesh Kamra, et al.
BMC Health Services Research|May 12, 2026
Harmonising research data to support mental health services decision making and care planning: development of a data harmonisation platform in regional AustraliaAgatha Conrad, Jamin Day, Ross Tynan, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapyJames McAuliffe, Hok Fung Chan, Laurine Noblecourt, et al.
Journal of Medical Virology|July 21, 2022
Concordance of B- and T-cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19Marc F Österdahl, Eleni Christakou, Deborah Hart, et al.
Cancer Research Communications|February 24, 2023
Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with CancerDuncan R McKenzie, Rosalind Graham, Thomas Lechmere, et al.
Journal for Immunotherapy of Cancer|June 28, 2020
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trialFederica Cappuccini, Richard Bryant, Emily Pollock, et al.
The Lancet. Rheumatology|November 15, 2021
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort studySatveer K Mahil, Katie Bechman, Antony Raharja, et al.
Pageof 3